GAMMA-INTERFERON AND RETINOIC ACID SYNERGIZE IN INHIBITING THE GROWTH OF HUMAN NEUROBLASTOMA-CELLS IN NUDE-MICE

被引:8
作者
CORNAGLIAFERRARIS, P
MARIOTTINI, GL
PONZONI, M
机构
[1] Pediatric Oncology Research Laboratory, G. Gaslini Children's Hospital
关键词
GAMMA-INTERFERON; RETINOIC ACID; NEUROBLASTOMA CELLS; NUDE MICE;
D O I
10.1016/0304-3835(92)90290-C
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have investigated the effects of retinoic acid (RA), human recombinant gamma interferon (gamma-IFN), and the association of both agents on the growth of human neuroblastoma (NB) cells in [CD1(nu/nu)] nude mice. Two human NB cell lines, namely LAN-5 and GI-LI-N, were previously adapted to grow in syngeneic animals for 7 consecutive passages. At the eight passage, only animals which developed 10-mm diameter tumors within 40 days from xenograft were admitted to the study. RA and/or gamma-IFN were administered subcutaneously 3-5 days per week for 3 consecutive weeks. The number of days necessary for each tumor mass to grow up to 20 mm diameter (in vivo doubling time, ivDT) was then evaluated. Tumor growth was significantly inhibited in gamma-IFN (P < 0.005) and RA (P < 0.05) treated mice grafted with GI-LI-N. The combination of the two agents did not further enhance ivDT. The tumor growth inhibition was not statistically significant in LAN-5 bearing mice treated with RA or gamma-IFN alone, while a synergistic effect between the two drugs was observed (P < 0.05). We conclude that parenteral combined administration of RA and gamma-IFN may prove to be useful in inhibiting the growth of tumors derived from human NB cells resistant to single inducers.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 22 条
[1]   HUMAN NEURO-BLASTOMA CELL-LINES AS MODELS FOR THE INVITRO STUDY OF NEOPLASTIC AND NEURONAL CELL-DIFFERENTIATION [J].
ABEMAYOR, E ;
SIDELL, N .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1989, 80 :3-15
[2]   MOLECULAR-CLONING AND EXPRESSION OF THE HUMAN INTERFERON-GAMMA RECEPTOR [J].
AGUET, M ;
DEMBIC, Z ;
MERLIN, G .
CELL, 1988, 55 (02) :273-280
[3]  
Cushing H, 1927, AM J PATHOL, V3, P203
[4]  
DANGIO GJ, 1971, LANCET, V1, P1046
[5]  
DINI G, 1991, P INT COURSE BMT S3, V7, P109
[6]  
Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49
[7]  
FAVROT MC, 1989, BONE MARROW TRANSPL, V4, P499
[8]  
GARAVENTA A, 1991, CANCER, V67, P922, DOI 10.1002/1097-0142(19910215)67:4<922::AID-CNCR2820670411>3.0.CO
[9]  
2-D
[10]  
HAAS D, 1988, CANCER, V62, P818, DOI 10.1002/1097-0142(19880815)62:4<818::AID-CNCR2820620430>3.0.CO